Open Multicentre Study of the Safety and Efficacy Against COVID-19 of Nirmatrelvir/Ritonavir in the Adult Population
Status:
Completed
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is open-labe randomized multicenter comparative Phase III study conducted in 11 medical
facilities. The objective of the study is to evaluate efficacy and safety of the drug
JTBC00201, tablets in the setting of pathogenetic and symptomatic therapy as compared to
standard therapy in outpatients with COVID-19.